Neurocritical Care News

In youth with Tourette syndrome and other persistent tic disorders, treatment with behavioral therapy was linked with symptom remission and a reduction in tic severity, according to a new study.

Biotechnology company bluebird bio announced that an FDA advisory committee has unanimously endorsed its gene therapy treatment for early active cerebral adrenoleukodystrophy.

Treatment with tenecteplase in an Australian mobile stroke unit was safe and resulted in improved outcomes compared with alteplase, according to a study published in The Lancet Neurology.

Known for his role as a pilot in “Star Wars,” actor Greg Grunberg has traded in his flight suit to travel cross country to bring awareness to epilepsy care, treatment and patient needs.

Biogen and Happify Health have announced a partnership to provide an artificial intelligence-powered digital solution for people with MS called Kopa, which will offer support for patients through education and engagement.

Long-term use of Xcopri was safe and reduced seizures by more than 90% in adults with uncontrolled focal seizures, according to results of an open-label extension study published in Neurology.

The FDA on June 23 announced a 5-year strategy for improving and extending the lives of people with rare neurodegenerative diseases by advancing development of safe and effective medical products and facilitating access to novel treatments.

Acadia Pharmaceuticals Inc. announced the outcome of the FDA advisory committee meeting on the use of pimavanserin for treating hallucinations and delusions associated with Alzheimer’s disease psychosis.

The FDA has approved Amvuttra, an RNA interference therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

CHARLOTTE, N.C. – Sleep disturbances were found to be highly prevalent and pervasive in patients with post-acute sequelae of COVID-19, Cinthya Pena Orbea, MD, said at the SLEEP meeting.